ATE275544T1 - Serinprotease-inhibitoren - Google Patents
Serinprotease-inhibitorenInfo
- Publication number
- ATE275544T1 ATE275544T1 AT01938386T AT01938386T ATE275544T1 AT E275544 T1 ATE275544 T1 AT E275544T1 AT 01938386 T AT01938386 T AT 01938386T AT 01938386 T AT01938386 T AT 01938386T AT E275544 T1 ATE275544 T1 AT E275544T1
- Authority
- AT
- Austria
- Prior art keywords
- serine protease
- protease inhibitors
- inhibitors
- factor
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrrole Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/GB2000/002302 WO2000076971A2 (en) | 1999-06-14 | 2000-06-13 | Serine protease inhibitors |
GBGB0030303.2A GB0030303D0 (en) | 2000-12-13 | 2000-12-13 | Compounds |
PCT/GB2001/002541 WO2001096296A1 (en) | 2000-06-13 | 2001-06-12 | Serine protease inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE275544T1 true ATE275544T1 (de) | 2004-09-15 |
Family
ID=9904936
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT01938386T ATE275544T1 (de) | 2000-06-13 | 2001-06-12 | Serinprotease-inhibitoren |
Country Status (10)
Country | Link |
---|---|
US (2) | US6878725B2 (de) |
EP (1) | EP1289950B1 (de) |
JP (1) | JP2004503532A (de) |
AT (1) | ATE275544T1 (de) |
AU (1) | AU2001264065A1 (de) |
CA (1) | CA2411798A1 (de) |
DE (1) | DE60105418T2 (de) |
ES (1) | ES2228874T3 (de) |
GB (1) | GB0030303D0 (de) |
WO (1) | WO2001096296A1 (de) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001264077B2 (en) * | 2000-06-13 | 2006-08-10 | Tularik Limited | Serine protease inhibitors |
EP1409479B1 (de) | 2001-07-26 | 2008-01-23 | Eli Lilly And Company | 1-glycinyl-4-(1-methylpiperidin-4-yl)piperazine und -piperidine als faktor-xa-antagonisten |
MY130373A (en) * | 2001-10-29 | 2007-06-29 | Malesci Sas | Linear basic compounds having nk-2 antagonist activity and formulations thereof |
US7030141B2 (en) | 2001-11-29 | 2006-04-18 | Christopher Franklin Bigge | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade |
NZ535402A (en) | 2002-04-01 | 2006-02-24 | Lilly Co Eli | Certain 1-(d-cyclopropylglycinyl)-4-(piperidin-4-yl) piperazine compounds as inhibitors of the serine protease factor Xa |
JP4980928B2 (ja) * | 2004-12-24 | 2012-07-18 | プロシディオン・リミテッド | Gタンパク質共役受容体(gpr116)作動薬および肥満および糖尿病治療のためのその使用 |
US8008327B2 (en) * | 2008-04-29 | 2011-08-30 | Boehringer Ingelheim International Gmbh | Indazole compounds as CCR1 receptor antagonists |
US8293917B2 (en) * | 2008-05-06 | 2012-10-23 | Boehringer Ingelheim International Gmbh | Pyrazole compounds as CCR1 antagonists |
AP2739A (en) * | 2008-09-26 | 2013-09-30 | Boehringer Ingelheim Int | Azaindazole compounds as CCRI receptor antagonists |
WO2010065799A2 (en) * | 2008-12-04 | 2010-06-10 | Palatin Technologies, Inc. | Amine substituted piperidine melanocortin receptor-specific compounds |
WO2011030537A1 (ja) * | 2009-09-08 | 2011-03-17 | 杏林製薬株式会社 | 4-(5-メチルピリジン-2-イルアミノ)ピペリジン-1-カルボン酸誘導体の製造方法 |
GEP20146103B (en) | 2009-10-21 | 2014-05-27 | Boehringer Ingelheim Int | Indazole and pyrazolopyridine compounds as ccr1 receptor antagonists |
WO2011056440A1 (en) | 2009-10-27 | 2011-05-12 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds as ccr1 receptor antagonists |
EP2509952A1 (de) * | 2009-12-08 | 2012-10-17 | Boehringer Ingelheim International GmbH | Verfahren zur synthese von zwischenprodukten zur herstellung von substituierten indazol- und azaindazolverbindungen |
JP5793182B2 (ja) | 2010-04-30 | 2015-10-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ccr1受容体アンタゴニストとしてのアザインダゾールアミド化合物 |
CN102464654B (zh) * | 2010-11-12 | 2016-01-13 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
WO2012087782A1 (en) | 2010-12-23 | 2012-06-28 | Boehringer Ingelheim International Gmbh | Pyrazolopiperidine compounds as ccr1 receptor antagonists |
JP6616821B2 (ja) | 2014-04-04 | 2019-12-04 | エックス−アールエックス, インコーポレイテッド | オートタキシンの置換スピロ環式阻害剤 |
JP6592008B2 (ja) * | 2014-04-23 | 2019-10-16 | エックス−アールエックス, インコーポレイテッド | オートタキシンの置換n−(2−アミノ)−2−オキソエチルベンズアミド阻害剤およびそれらの調製、ならびにlpa依存性またはlpa媒介性疾患の処置における使用 |
KR102099608B1 (ko) * | 2017-11-17 | 2020-04-10 | 성균관대학교산학협력단 | 퀴놀린-8-일메탄아민, 이의 제조방법 및 이를 유효성분으로 포함하는 암 예방 및 치료용 조성물 |
CA3148310A1 (en) * | 2019-09-13 | 2021-03-18 | Jun Qi | Kdm inhibitors and uses thereof |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5346907A (en) | 1988-04-05 | 1994-09-13 | Abbott Laboratories | Amino acid analog CCK antagonists |
IE902295A1 (en) | 1989-07-07 | 1991-01-16 | Abbott Lab | Amino acid analog cck antagonists |
CA2200163A1 (en) | 1996-03-22 | 1997-09-22 | Michael Robert Wiley | Antithrombotic diamides |
WO1997049404A1 (en) | 1996-06-25 | 1997-12-31 | Eli Lilly And Company | Anticoagulant agents |
IL123986A (en) | 1997-04-24 | 2011-10-31 | Organon Nv | Medicinal compounds |
JP2002512633A (ja) | 1997-06-26 | 2002-04-23 | イーライ・リリー・アンド・カンパニー | 抗血栓剤 |
EP1007037A4 (de) | 1997-06-26 | 2004-10-06 | Lilly Co Eli | Antithrombose mittel |
ATE297203T1 (de) | 1997-06-26 | 2005-06-15 | Lilly Co Eli | Antithrombotische mitteln |
IL133627A0 (en) | 1997-06-26 | 2001-04-30 | Lilly Co Eli | Antithrombotic agents |
EP1009758B1 (de) | 1997-08-29 | 2005-06-01 | Tularik Limited | Meta-benzamidinderivate als serinprotease-inhibitoren |
US6740682B2 (en) * | 1997-08-29 | 2004-05-25 | Tularik Limited | Meta-benzamidine derivatives as serine protease inhibitors |
AU753675B2 (en) * | 1998-03-19 | 2002-10-24 | Ajinomoto Co., Inc. | Aminoisoquinoline derivatives |
US6635657B1 (en) | 1998-12-23 | 2003-10-21 | Eli Lilly And Company | Aromatic amides |
AU2054700A (en) | 1998-12-23 | 2000-07-31 | Eli Lilly And Company | Antithrombotic amides |
CA2358095A1 (en) | 1998-12-23 | 2000-07-06 | Eli Lilly And Company | Heteroroaromatic amides as inhibitor of factor xa |
EP1140839B1 (de) | 1998-12-24 | 2004-03-17 | Eli Lilly And Company | Heterocyclische amide als inhibitoren von faktor xa |
WO2000071507A2 (en) | 1999-05-24 | 2000-11-30 | Cor Therapeutics, Inc. | INHIBITORS OF FACTOR Xa |
EP1185508A2 (de) | 1999-05-24 | 2002-03-13 | Cor Therapeutics, Inc. | Inhibitoren von faktor xa |
CA2383008A1 (en) * | 1999-06-14 | 2000-12-21 | Amanda Jane Lyons | Compounds |
DE60022508T2 (de) | 1999-06-14 | 2006-06-08 | Eli Lilly And Co., Indianapolis | Inhibitoren von serin proteasen |
GB9929552D0 (en) * | 1999-12-14 | 2000-02-09 | Proteus Molecular Design | Compounds |
US7074934B2 (en) * | 2000-06-13 | 2006-07-11 | Tularik Limited | Serine protease inhibitors |
GB0030306D0 (en) * | 2000-12-13 | 2001-01-24 | Lilly Co Eli | Compounds |
-
2000
- 2000-12-13 GB GBGB0030303.2A patent/GB0030303D0/en not_active Ceased
-
2001
- 2001-06-12 AU AU2001264065A patent/AU2001264065A1/en not_active Abandoned
- 2001-06-12 US US10/030,189 patent/US6878725B2/en not_active Expired - Fee Related
- 2001-06-12 JP JP2002510440A patent/JP2004503532A/ja not_active Withdrawn
- 2001-06-12 ES ES01938386T patent/ES2228874T3/es not_active Expired - Lifetime
- 2001-06-12 DE DE60105418T patent/DE60105418T2/de not_active Expired - Fee Related
- 2001-06-12 AT AT01938386T patent/ATE275544T1/de not_active IP Right Cessation
- 2001-06-12 WO PCT/GB2001/002541 patent/WO2001096296A1/en active IP Right Grant
- 2001-06-12 CA CA002411798A patent/CA2411798A1/en not_active Abandoned
- 2001-06-12 EP EP01938386A patent/EP1289950B1/de not_active Expired - Lifetime
-
2004
- 2004-06-28 US US10/876,672 patent/US20040242656A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2004503532A (ja) | 2004-02-05 |
US20040242656A1 (en) | 2004-12-02 |
EP1289950B1 (de) | 2004-09-08 |
AU2001264065A1 (en) | 2001-12-24 |
EP1289950A1 (de) | 2003-03-12 |
US20030078438A1 (en) | 2003-04-24 |
GB0030303D0 (en) | 2001-01-24 |
ES2228874T3 (es) | 2005-04-16 |
CA2411798A1 (en) | 2001-12-20 |
DE60105418D1 (de) | 2004-10-14 |
US6878725B2 (en) | 2005-04-12 |
DE60105418T2 (de) | 2005-09-15 |
WO2001096296A1 (en) | 2001-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA02011411A (es) | Inhibidores de proteasa de serina. | |
ATE304532T1 (de) | Inhibitoren von serin proteasen | |
DE60105418D1 (de) | Serinprotease-inhibitoren | |
DE60022508D1 (de) | Inhibitoren von serin proteasen | |
WO2000076970A3 (en) | Serine protease inhibitors | |
ATE355284T1 (de) | Inhibitoren von serinproteasen | |
GB0030306D0 (en) | Compounds | |
DE60126978D1 (de) | Inhibitoren von serin proteasen | |
MXPA03006224A (es) | Inhibidores de cruzipaina y otras proteasas de cisteina. | |
ATE287403T1 (de) | 6-phenylbenzonaphthyidine | |
ATE348803T1 (de) | Tryptase-inhibitoren | |
ATE364037T1 (de) | Tryptasehemmer | |
ATE344795T1 (de) | Inhibitoren von serinproteasen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |